<DOC>
	<DOC>NCT00729053</DOC>
	<brief_summary>- Multi-Center - Randomized - Open-Label Study of single agent IMO-2055 - Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)</brief_summary>
	<brief_title>Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma</brief_title>
	<detailed_description>This is a study of 2 dose levels (0.16 or 0.64 mg/kg) of IMO-2055 administered by weekly subcutaneous (SC) injections in two patient populations, treatment na√Øve or previously treated patients. Each dose group (treatment naive or previously treated) will be randomized to receive one of the 2 doses being studied.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>Histologically confirmed stage IV clear cell renal carcinoma with metastatic or locally recurrent disease that is not surgically resectable. At least one measurable lesion Adequate organ function Any prior treatment of renal cell cancer was concluded at least 4 weeks prior. If female and of childbearing potential, a negative serum pregnancy test performed and documented no more than 14 days before the first dose of study drug. Known untreated central nervous system (CNS) metastasis Preexisting autoimmune or antibodymediated diseases Other significant medical disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>renal</keyword>
	<keyword>cell</keyword>
	<keyword>renal carcinoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>recurrent</keyword>
	<keyword>treatment naive</keyword>
</DOC>